Immunotherapy Drugs Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 8.41 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The Immunotherapy Drugs Market was valued at USD 164.68 billion in 2020, and it is expected to reach USD 276.51 billion by 2026, registering a CAGR of 8.41% during the forecast period.
As per research studies, immunotherapies as an adjunct therapy in severe COVID-19 cases. Immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation.
The impact of COVID-19 on the immunotherapy drugs market is positive because many companies are currently focused on developing immunotherapy-based drugs or vaccines for COVID-19. Currently, BioNTech SE, in collaboration with Pfizer Inc., is conducting a phase III clinical trial to assess the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in healthy participants.
The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies.
Furthermore, factors such as growing research collaborations, increasing number of research laboratories, and growing direct and indirect investments in research and development (R&D) by pharmaceutical and biotechnology companies will also support the market's growth in the coming years. For instance, in 2019, Gilead Sciences Inc. and Humanigen Inc. collaborated to jointly study lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma.
Globally, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Major chronic diseases include cancer, kidney failure, autoimmune and inflammatory diseases, and heart diseases. For instance, as per Versus Arthritis, in 2019, it was estimated that over 18% of people who were above 45 years of age in England had osteoarthritis of the knee.
In addition, according to a research article by Matthew Gowshall et al., published in International Journal of General medicine 2018, mortality from many non-communicable diseases (NCDs) or chronic diseases continues to increase worldwide, with a disproportionately larger impact in low-middle income countries (LMIs), with almost 75% of global deaths occur from chronic diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization.
For instance, according to the GLOBOCAN 2020 data, globally, in 2020, the total number of new cancer cases was found to be 9,227,484, indicating that it had risen to 19.3 million cases and 10 million cancer deaths in 2020. Lung cancer and prostate cancer are the most common among men, accounting for nearly one-third of all male cancers.
The current trends of nanotechnology in immunotherapy will boost market growth. The nanoparticles, which have dimensions of less than 100 nanometers, have been engineered to treat cancer. The benefits provided are active or passive attack of drugs, high solubility bioavailability, and multifunctionality.
Overall, the rising R&D activities in developing novel immunotherapies for various chronic diseases are anticipated to drive the global immunotherapy drugs market’s growth.
Scope of the Report
As per the scope of the report, immunotherapy is a type of therapy that uses drugs to suppress or stimulate the immune system to help the body fight against infection, cancer, and other diseases. It relates to a type of biological therapy for cancer treatment to boost the body’s natural defenses to fight cancer. It may work in stopping or slowing the growth of cancer cells, stopping cancer from spreading in other parts of the body, and in the improvement of the immune system. These therapies are made by the body or in a laboratory to improve or restore immune system function. The Immunotherapy Drugs Market is segmented by Type of Drug (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins, and Other Types of Drugs), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Other Therapy Areas), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD billion) for the above segments.
| By Type of Drug | |
| Monoclonal Antibodies | |
| Vaccines | |
| Interferons Alpha and Beta | |
| Interleukins | |
| Other Types of Drugs |
| By Therapy Area | |
| Cancer | |
| Autoimmune and Inflammatory Diseases | |
| Infectious Diseases | |
| Other Therapy Areas |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Cancer is Expected to Hold Significant Market Share in the Therapy Area Segment Over the Forecast Period
- Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the GLOBOCAN data, in 2020, there were around 2,261,419 (11.7%) new breast cancer cases, 2,206,771 (11.4%) new lung cancer cases and 1,931,590 (10%) new colorectum cancer cases. Breast cancer represents 1 in 4 cancers diagnosed among women globally. Colorectal, lung, cervical, and thyroid cancers are also common among women. This cancer incidence is expected to rise in the coming years, helping the market grow.
- There are several types of immunotherapies used for the treatment of cancer. Some immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators. These therapies are used for many types of cancer and their advanced stages. Some of the popular immunotherapy drugs include Rituxan, Yervoy, Adcetris, and Zevalin.
- The market players are launching new products for cancer treatment, which is expected to boost the market growth. For instance, in July 2019, Amgen Inc. and Allergan PLC launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) in the United States. MVASI, the first oncology therapeutic biosimilar approved by the US Food and Drug Administration (FDA) for treating five types of cancers such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, and others.
- The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns to raise awareness regarding several kinds of cancer. For instance, according to the National Clinical Trial (NCT) Registry, Novartis Pharmaceuticals is conducting a phase Ib, open-label, dose-escalation study of spartalizumab plus LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose-expansion in adult patients with advanced or metastatic triple-negative breast cancer (TNBC). The trial started in January 2019 and is expected to be complete in January 2022.
- Thus, the factors mentioned above are expected to show significant growth over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and it is Expected to do the Same in the Forecast Period
North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.
People with cancer are at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-2-CoV) virus that causes COVID-19. Thus, researchers are in the development of effective therapeutics for COVID-19. For instance, the Canadian Cancer Trials Group is conducting a phase III clinical trial to determine if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
According to the estimates of the Globocan, in 2020, there were around 2,556,862 new cancer cases diagnosed and 699,274 deaths due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.
According to the National Clinical Trial Registry (NCT), as of March 4, 2021, in the United States, there were six interventional clinical trials across different phases of development to investigate the current coronavirus disease (COVID-19). This indicates researchers across the United States are underway to develop vaccines or drugs in the treatment of COVID-19 disease. This indicates the effectiveness of immunotherapy across different therapy areas, which is expected to boost the market in the near future.
In the North American region, the United States holds the largest market share. Factors such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, increasing R&D activities, and rising new product launches are the primary factors propelling the immunotherapy market in the United States. For instance, in May 2019, Humanigen Inc. and Kite (Gilead Sciences, Inc.) collaborated to study lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma.
In addition, in March 2019, Roche’s Tecentriq, combined with Abraxane, received US FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer. Therefore, increasing research and development activities along the rising burden of chronic diseases is expected to drive market growth over the forecast period.
To understand geography trends, Download Sample Report
Competitive Landscape
The immunotherapy drugs market is moderately fragmented and highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches, R&D, expansions to gain a competitive advantage. In August 2019, US FDA approved pexidartinib (TURALIO, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the market's major players include AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG.
Recent Developments
In February 2021, Regeneron Pharmaceuticals Inc. received US FDA approval for cemiplimab-rwlc (Libtayo) immunotherapy drug for first-line treatment for Non-small-cell lung carcinoma (NSCLC) patients with high PD-L1 expression and who are not eligible for surgery or chemoradiation.
In May 2020, FDA approved the combination ramucirumab and erlotinib for first-line treatment of non-small-cell lung cancer patients with the EGFR exon 19 or exon 21 mutations.
In May 2020, in India, the University of Hyderabad (UoH) and the CSIR-Centre for Cellular and Molecular Biology collaborated with Vins Bioproducts Ltd company to develop antibody fragment-based immunotherapy for the treatment of COVID-19.
In March 2020, the US Food and Drug Administration (FDA) approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC).
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
4.2.2 Emergence of Biosimilars
4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.4 Rising Demand for Monoclonal Antibodies
4.3 Market Restraints
4.3.1 High Cost of Immunotherapy Treatment
4.3.2 High Attrition Rate in the Product Development Cycle
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Drug
5.1.1 Monoclonal Antibodies
5.1.2 Vaccines
5.1.3 Interferons Alpha and Beta
5.1.4 Interleukins
5.1.5 Other Types of Drugs
5.2 By Therapy Area
5.2.1 Cancer
5.2.2 Autoimmune and Inflammatory Diseases
5.2.3 Infectious Diseases
5.2.4 Other Therapy Areas
5.3 Geography
5.3.1 North America
5.3.1.1 United States (By Type of Drugs and Therapy Area)
5.3.1.2 Canada (By Type of Drugs and Therapy Area)
5.3.1.3 Mexico (By Type of Drugs and Therapy Area)
5.3.2 Europe
5.3.2.1 Germany (By Type of Drugs and Therapy Area)
5.3.2.2 United Kingdom (By Type of Drugs and Therapy Area)
5.3.2.3 France (By Type of Drugs and Therapy Area)
5.3.2.4 Italy (By Type of Drugs and Therapy Area)
5.3.2.5 Spain (By Type of Drugs and Therapy Area)
5.3.2.6 Rest of Europe (By Type of Drugs and Therapy Area)
5.3.3 Asia-Pacific
5.3.3.1 China (By Type of Drugs and Therapy Area)
5.3.3.2 Japan (By Type of Drugs and Therapy Area)
5.3.3.3 India (By Type of Drugs and Therapy Area)
5.3.3.4 Australia (By Type of Drugs and Therapy Area)
5.3.3.5 South Korea (By Type of Drugs and Therapy Area)
5.3.3.6 Rest of Asia-Pacific (By Type of Drugs and Therapy Area)
5.3.4 Middle-East and Africa
5.3.4.1 GCC (By Type of Drugs and Therapy Area)
5.3.4.2 South Africa (By Type of Drugs and Therapy Area)
5.3.4.3 Rest of Middle-East and Africa (By Type of Drugs and Therapy Area)
5.3.5 South America
5.3.5.1 Brazil (By Type of Drugs and Therapy Area)
5.3.5.2 Argentina (By Type of Drugs and Therapy Area)
5.3.5.3 Rest of South America (By Type of Drugs and Therapy Area)
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bristol-Myers Squibb
6.1.5 F. Hoffmann-La Roche AG
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 UbiVac
6.1.11 Pfizer Inc.
6.1.12 Bayer AG
6.1.13 Sanofi
6.1.14 Boehringer Ingelheim
6.1.15 Gilead Sciences Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Immunotherapy Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Global Immunotherapy Drugs Market?
The Global Immunotherapy Drugs Market is growing at a CAGR of 8.41% over the next 5 years.
What is Global Immunotherapy Drugs Market size in 2018?
The Global Immunotherapy Drugs Market is valued at 164 Billion USD in 2018.
What is Global Immunotherapy Drugs Market size in 2026?
The Global Immunotherapy Drugs Market is valued at 276 Billion USD in 2026.
Which region has highest growth rate in Global Immunotherapy Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Immunotherapy Drugs Market?
North America holds highest share in 2020.
Who are the key players in Global Immunotherapy Drugs Market?
GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Amgen Inc., Novartis AG, AbbVie Inc. are the major companies operating in Global Immunotherapy Drugs Market.
